Redeye views the Q1 report as a confirmation of the progress made with the first sales of Terclara in the books and processes proceeding as planned, with a primary focus on the Swedish launch, the phase 3 US study, and the Terbinafine supply issue. The actual report was roughly in line with our expectations even if sales were slightly higher than expected. We adjust our expectations slightly upwards for the potential outcome of the TO, with other estimates essentially unchanged.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/